A CD19/CD20-targeting TanCAR (LV20.19 or zamtocabtagene autoleucel) tested in a phase I trial for R/R B-NHL achieved a 100% ORR and 92% CR rate in patients treated at the target dose, and preliminary data of phase II studies confirmed deep and durable responses in R/R LBCL setting [140,141]. Here, CD19 is linked to non-Hodgkin lymphoma.